Titre : ADP ribose transferases

ADP ribose transferases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Language Development Disorders
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "ADP ribose transferases : Questions médicales les plus fréquentes", "headline": "ADP ribose transferases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les ADP ribose transferases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-30", "dateModified": "2025-04-24", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "ADP ribose transferases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pentosyltransferases", "url": "https://questionsmedicales.fr/mesh/D010430", "about": { "@type": "MedicalCondition", "name": "Pentosyltransferases", "code": { "@type": "MedicalCode", "code": "D010430", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "NAD nucleosidase", "alternateName": "NAD+ Nucleosidase", "url": "https://questionsmedicales.fr/mesh/D009244", "about": { "@type": "MedicalCondition", "name": "NAD nucleosidase", "code": { "@type": "MedicalCode", "code": "D009244", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.660" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "ADP-ribosyl cyclase", "alternateName": "ADP-ribosyl Cyclase", "url": "https://questionsmedicales.fr/mesh/D036541", "about": { "@type": "MedicalCondition", "name": "ADP-ribosyl cyclase", "code": { "@type": "MedicalCode", "code": "D036541", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.660.060" } } } ] }, { "@type": "MedicalWebPage", "name": "Poly(ADP-ribose) polymerases", "alternateName": "Poly(ADP-ribose) Polymerases", "url": "https://questionsmedicales.fr/mesh/D011065", "about": { "@type": "MedicalCondition", "name": "Poly(ADP-ribose) polymerases", "code": { "@type": "MedicalCode", "code": "D011065", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.690" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Poly (ADP-Ribose) polymerase-1", "alternateName": "Poly (ADP-Ribose) Polymerase-1", "url": "https://questionsmedicales.fr/mesh/D000071137", "about": { "@type": "MedicalCondition", "name": "Poly (ADP-Ribose) polymerase-1", "code": { "@type": "MedicalCode", "code": "D000071137", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.690.420" } } }, { "@type": "MedicalWebPage", "name": "Tankyrases", "alternateName": "Tankyrases", "url": "https://questionsmedicales.fr/mesh/D038501", "about": { "@type": "MedicalCondition", "name": "Tankyrases", "code": { "@type": "MedicalCode", "code": "D038501", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.690.840" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "ADP ribose transferases", "alternateName": "ADP Ribose Transferases", "code": { "@type": "MedicalCode", "code": "D036002", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anthony K L Leung", "url": "https://questionsmedicales.fr/author/Anthony%20K%20L%20Leung", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA." } }, { "@type": "Person", "name": "Morgan Dasovich", "url": "https://questionsmedicales.fr/author/Morgan%20Dasovich", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA." } }, { "@type": "Person", "name": "Mohsen Badiee", "url": "https://questionsmedicales.fr/author/Mohsen%20Badiee", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205." } }, { "@type": "Person", "name": "Yong Zhang", "url": "https://questionsmedicales.fr/author/Yong%20Zhang", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States." } }, { "@type": "Person", "name": "Sua Myong", "url": "https://questionsmedicales.fr/author/Sua%20Myong", "affiliation": { "@type": "Organization", "name": "Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The Engage with Developmental Language Disorder (E-DLD) project: Cohort profile.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36565246", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1460-6984.12835" } }, { "@type": "ScholarlyArticle", "name": "Development and Validation of a Language Screening for Implementation in Pre-School Settings.", "datePublished": "2022-06-22", "url": "https://questionsmedicales.fr/article/35812510", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.866598" } }, { "@type": "ScholarlyArticle", "name": "Identifying Language Disorder in Bilingual Children Using Automatic Speech Recognition.", "datePublished": "2022-07-12", "url": "https://questionsmedicales.fr/article/35858259", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1044/2022_JSLHR-21-00667" } }, { "@type": "ScholarlyArticle", "name": "Describing the Spoken Language Skills of Typically Developing Afrikaans-Speaking Children Using Language Sample Analysis: A Pilot Study.", "datePublished": "2023-02-14", "url": "https://questionsmedicales.fr/article/36787151", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1044/2022_LSHSS-22-00077" } }, { "@type": "ScholarlyArticle", "name": "The impact of developmental language disorder in a defendant's description on mock jurors' perceptions and judgements.", "datePublished": "2022-09-10", "url": "https://questionsmedicales.fr/article/36087284", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1460-6984.12779" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Transferases", "item": "https://questionsmedicales.fr/mesh/D014166" }, { "@type": "ListItem", "position": 5, "name": "Glycosyltransferase", "item": "https://questionsmedicales.fr/mesh/D016695" }, { "@type": "ListItem", "position": 6, "name": "Pentosyltransferases", "item": "https://questionsmedicales.fr/mesh/D010430" }, { "@type": "ListItem", "position": 7, "name": "ADP ribose transferases", "item": "https://questionsmedicales.fr/mesh/D036002" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : ADP ribose transferases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur ADP ribose transferases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur ADP ribose transferases", "description": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?\nQuels marqueurs biochimiques sont associés aux ADP ribose transferases ?\nY a-t-il des tests spécifiques pour les ADP ribose transferases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests d'imagerie sont-ils utiles pour ces enzymes ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Language+Development+Disorders&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur ADP ribose transferases", "description": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?\nPeut-on observer des symptômes neurologiques ?\nLes symptômes varient-ils selon le type d'enzyme ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes sont-ils toujours présents ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Language+Development+Disorders&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur ADP ribose transferases", "description": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'exercice physique aide-t-il à prévenir ces dysfonctionnements ?\nLes vaccinations ont-elles un rôle préventif ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Language+Development+Disorders&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur ADP ribose transferases", "description": "Quels traitements existent pour les dysfonctionnements enzymatiques ?\nLes suppléments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements sont-ils curatifs ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Language+Development+Disorders&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur ADP ribose transferases", "description": "Quelles complications peuvent survenir avec ces dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies cardiovasculaires ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles prévisibles ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Language+Development+Disorders&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur ADP ribose transferases", "description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe stress a-t-il un impact sur ces enzymes ?\nLes antécédents familiaux influencent-ils le risque ?\nL'alimentation joue-t-elle un rôle ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Language+Development+Disorders&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour évaluer leur activité." } }, { "@type": "Question", "name": "Quels marqueurs biochimiques sont associés aux ADP ribose transferases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux d'ADP-ribose libre et de protéines modifiées peuvent servir de marqueurs." } }, { "@type": "Question", "name": "Y a-t-il des tests spécifiques pour les ADP ribose transferases ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des ADP ribose transferases." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la réparation de l'ADN ou des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les tests d'imagerie sont-ils utiles pour ces enzymes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, les tests d'imagerie ne sont pas utilisés pour diagnostiquer les dysfonctionnements enzymatiques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la réparation de l'ADN, des maladies neurodégénératives et des cancers." } }, { "@type": "Question", "name": "Peut-on observer des symptômes neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs et des problèmes de mémoire peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type d'enzyme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, différents types d'ADP ribose transferases peuvent entraîner des symptômes variés." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent apparaître en raison de troubles métaboliques liés aux enzymes." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques malgré une dysfonction enzymatique." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines et à des radiations peut affecter l'activité enzymatique." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages peuvent être utiles pour les personnes à risque élevé de maladies associées." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à prévenir ces dysfonctionnements ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et enzymatique." } }, { "@type": "Question", "name": "Les vaccinations ont-elles un rôle préventif ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccinations ne sont pas directement liées à la prévention des dysfonctionnements enzymatiques." } }, { "@type": "Question", "name": "Quels traitements existent pour les dysfonctionnements enzymatiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblés peuvent être envisagés." } }, { "@type": "Question", "name": "Les suppléments peuvent-ils aider ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments d'ADP-ribose peuvent être envisagés, mais leur efficacité n'est pas prouvée." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques sur des inhibiteurs spécifiques des ADP ribose transferases sont en cours." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du type de dysfonctionnement enzymatique." } }, { "@type": "Question", "name": "Les traitements sont-ils curatifs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, la plupart des traitements visent à gérer les symptômes plutôt qu'à guérir la condition." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces dysfonctionnements ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des cancers, des maladies auto-immunes et des troubles neurologiques peuvent se développer." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies cardiovasculaires ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent un lien entre dysfonctionnement enzymatique et maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées en fonction des antécédents médicaux." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques, l'exposition à des toxines et le mode de vie jouent un rôle." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter l'activité des ADP ribose transferases." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur ces enzymes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress oxydatif peut altérer l'activité des ADP ribose transferases." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies liées peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut réduire le risque de dysfonctionnement enzymatique." } } ] } ] }

Sources (10000 au total)

The Engage with Developmental Language Disorder (E-DLD) project: Cohort profile.

Public awareness of Developmental Language Disorder (DLD) is lower than other neurodevelopmental disorders, despite its high prevalence of 7.6%. This lower awareness means recruitment for DLD research... This paper aims to describe the families of children with DLD and adults with DLD in the database thus far.... E-DLD members sign up via our website, reporting demographic characteristics as part of this procedure. We request all E-DLD members subsequently fill in a yearly survey. The content of the yearly sur... The database currently consists of 196 parents of children with DLD and 20 individuals over the age of 16 with DLD or suspected DLD across a range of socioeconomic status (SES) backgrounds. Our initia... The findings indicate that a participant database for DLD research is feasible and useful. The rates of emotional, behavioural and sleep difficulties among the child probands are higher than reported ... What is already known on this subject Developmental Language Disorder (DLD) is characterised by expressive and/or receptive language difficulties in the absence of another biomedical condition that co...

Development and Validation of a Language Screening for Implementation in Pre-School Settings.

To prevent or mitigate long-lasting learning problems and emotional, behavioral, and social-adaption difficulties associated with language disorders, age-appropriate German language competence at scho... To develop a screening instrument to identify increased risk of LD and to evaluate its validity and feasibility within the constraints of regular universal pre-school language screening.... A two-component screening instrument including direct assessment of expressive and receptive grammar was used in a sample of 374 children with German as their dominant language attending a public pre-... The combination of the expressive and receptive grammar scales demonstrated excellent accuracy (area under the curve score 0.928). A cut-off of 18 resulted in a failing rate of 21.8% and showed good s...

Identifying Language Disorder in Bilingual Children Using Automatic Speech Recognition.

The differential diagnosis of developmental language disorder (DLD) in bilingual children represents a unique challenge due to their distributed language exposure and knowledge. The current evidence i... Eighty-four Spanish-English bilingual second graders with (... Results demonstrated moderate overall item-by-item scoring agreement (... This study provides preliminary support for the technical feasibility of ASR as a bilingual expressive language assessment tool.... https://doi.org/10.23641/asha.20249994....

Describing the Spoken Language Skills of Typically Developing Afrikaans-Speaking Children Using Language Sample Analysis: A Pilot Study.

Language sample analysis is widely regarded as the gold standard of language assessment. However, the uncertainty regarding the optimal length of sample and the limited availability of developmental l... The study involved 30 typically developing Afrikaans-speaking children aged between 3;6 and 9;6 (years;months). A descriptive research design was used to transcribe and analyze 1-hr interactions colle... Results indicated that mean length of utterance in words per minute, number of different words per minute, and total number of words per minute stabilized at 30 min and no significant differences were... The study concluded that a 30-min interaction segment provides a representative language sample for Afrikaans-speaking children who are between 3;6 and 9;6. It provides promising preliminary developme...

The impact of developmental language disorder in a defendant's description on mock jurors' perceptions and judgements.

While it has been posited that young people with language needs may be viewed more negatively (e.g., as more rude, less cooperative) than those without language needs, the impact of knowing about a pe... To examine whether the presence of a developmental language disorder (DLD) diagnosis in a defendant's information would affect mock juror ratings of guilt, sentence length, credibility and blameworthi... A total of 143 jury eligible participants read a vignette of a non-violent crime. Half of the participants (N = 73) were told the defendant has a diagnosis of DLD, while half (N = 70) were not told.... Preregistered analyses found that DLD information affected ratings of credibility and blameworthiness, though not judgements of guilt or sentence length. Unregistered content analyses were applied to ... Unlike in previous studies of the impact of autism information, information about a defendant's DLD did not affect mock jurors' likelihood of finding them guilty, or lead participants to give longer s... What is already known on the subject There is already evidence that some conditions that affect communication, specifically autism, also affect juror perceptions. Research also shows that knowing whet...

Predictors of school concern across the transition to secondary school with developmental language disorder and low language ability: A longitudinal developmental cascade analysis.

Developmental language disorder (DLD) has clear functional ramifications in the areas of social competency, emotion recognition, emotional well-being and literacy skill, which have been found to persi... To investigate the association between psychosocial domains, literacy skill and concerns about school during the transition to secondary school for adolescents with DLD, LL and their TD peers. The fir... Participants (aged 10-11 years) with DLD (n = 30), LL ((n = 29) and TD (n = 42) were recruited for this longitudinal study from eight UK primary schools. Standardized language and psychosocial assessm... Regression analyses showed pre-transition school concern to be predicted by emotion recognition for the DLD group, by social competence and emotional well-being for the LL group, and by social compete... This study concludes that transition interventions must be differentiated according to language ability; support for DLD adolescents should focus on emotion recognition skill, provision for LL adolesc... What is already known on the subject There is limited research exploring the transition from primary school to secondary for adolescents with DLD or LL ability. Research on TD has highlighted vulnerab...

Acoustic and Kinematic Methods of Indexing Spatiotemporal Stability in Children With Developmental Language Disorder.

The spatiotemporal index (STI) is a standard metric for quantifying the stability and patterning of speech movements. The STI has often been applied to individual speech articulators, but an STI deriv... A total of 85 children with DLD and with typical language development (or typically developing [TD] children), aged 4-8 years, were studied. In this methodological article, two experiments were conduc... In sentence production, most group differences aligned across kinematic and acoustic STI measures. The acoustic, but not the kinematic, STI showed higher variability in children with DLD compared with... The kinematic and acoustic STIs assess different components of speech movement patterning. However, the relationship between acoustic and kinematic spatiotemporal stability is strong in two tasks of v...

Association of Developmental Language Disorder With Comorbid Developmental Conditions Using Algorithmic Phenotyping.

Developmental language disorder (DLD) is a common (with up to 7% prevalence) yet underdiagnosed childhood disorder whose underlying biological profile and comorbidities are not fully understood, espec... To identify clinically relevant conditions that co-occur with DLD at the population level.... This case-control study used an electronic health record (EHR)-based population-level approach to compare the prevalence of comorbid health phenotypes between DLD cases and matched controls. These cas... Common and rare comorbidities of DLD at the population level were identified using EHRs and a phecode-based enrichment analysis.... Comorbidity analysis was conducted for 5273 DLD cases (mean [SD] age, 16.8 [7.2] years; 3748 males [71.1%]) and 26 353 matched controls (mean [SD] age, 14.6 [5.5] years; 18 729 males [71.1%]). Relevan... This study found both rare and common comorbidities of DLD. Comorbidity profiles may be leveraged to identify risk of additional health challenges, beyond language impairment, among children with DLD....